Search

In this study we report the green synthesis of nontoxic and stable Cu nanoparticles (NP) using chitosan/starch hydrogel with reducing/capping ability without using any harsh reducing agents. Starch was used as a reducing agent for the synthesis of Cu NPs that was further stabilized by chitosan polymers. The in situ prepared Cu NPs/CS-Starch bio-composite were characterized by advanced physicochemical techniques like Fourier Transformed Infrared spectroscopy (FT-IR), Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), Energy Dispersive X-ray spectroscopy (EDX), X-ray Diffraction (XRD), UV–Vis, TGA and Inductively Coupled Plasma-Optical Emission Spectroscopic (ICP-OES) study. It has been established that Cu NPs/CS-Starch bio-composite have a spherical shape with a mean diameter from 5 to 7 nm. Cell viability of Cu NPs/CS-Starch bio-composite was very low against common human thyroid carcinoma cell lines i.e. TPC1, BCPAP and FTC133 without any cytotoxicity on normal cell line. The best anti-human thyroid carcinoma effects of Cu NPs/CS-Starch bio-composite was observed against the TPC1 cell line. For investigating the antioxidant properties of Cu NPs/CS-Starch bio-composite, the DPPH assay was used in the presence of butylated hydroxytoluene as the positive control. Cu NPs/CS-Starch bio-composite inhibited half of the DPPH molecules in the concentration of 207 µg/mL. The antioxidant activity of Cu NPs/CS-Starch bio-composite is significantly related to its anti-human thyroid carcinoma potentials. Based on to the above findings, the Cu NPs/CS-Starch bio-composite could be administrated for the treatment of several types of human thyroid carcinoma in humans.

All- trans retinoic acid (ATRA) is an anti-tumor compound, exerting different anti-cancer effects on different types of cancer cells. Unfortunately, retinoids are also characterized by certain side effects following systemic administration, such as the burning of skin and general malaise. The highly variable degree of bioavailability of ATRA plus its tendency to induce its own destruction through metabolic degradation following oral treatment necessitate the development of alternative formulations. The aim of this work is to evaluate the physico-chemical properties of unilamellar, ATRA-containing liposomes and to investigate the cytotoxic activity of this potential nanomedicine on human thyroid carcinoma cells. Liposomes made up of DPPC/Chol/DSPE-mPEG2000 (6:3:1 molar ratio), characterized by a mean diameter of ∼200 nm, a polydispersity index of 0.1 and a negative surface charge, were used as ATRA-carriers and their antiproliferative efficacy was investigated in comparison with the free drug on three different human thyroid carcinoma cell lines (PTC-1, B-CPAP, and FRO) through MTT-testing. The liposomes protected the ATRA against photodegradation and increased its antiproliferative properties due to the improvement of its cellular uptake. ATRA-loaded liposomes could be a novel formulation useful for the treatment of anaplastic thyroid carcinoma. [ABSTRACT FROM AUTHOR]

Novel therapeutic approaches are required for the less differentiated thyroid cancers which are non-responsive to the current treatment. In this study we tested an innovative formulation of nanoliposomes containing sildenafil citrate or tadalafil, phosphodiesterase-5 inhibitors, on two human thyroid cancer cell lines (TPC-1 and BCPAP). Nanoliposomes were prepared by the thin layer evaporation and extrusion methods, solubilizing the hydrophilic compound sildenafil citrate in the aqueous phase during the hydration step and dissolving the lipophilic tadalafil in the organic phase. Nanoliposomes, made up of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine monohydrate (DPPC), cholesterol, and N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-mPEG2000) (6:3:1 molar ratio), were characterized by a mean diameter of ~100 nm, a very low polydispersity index (~0.1) and a negative surface charge. The drugs did not influence the physico-chemical properties of the systems and were efficiently retained in the colloidal structure. By using cell count and MTT assay, we found a significant reduction of the viability in both cell lines following 24 h treatment with both nanoliposomal-encapsulated drugs, notably greater than the effect of the free drugs. Our findings demonstrate that nanoliposomes increase the antiproliferative activity of phosphodiesterase-5 inhibitors, providing a useful novel formulation for the treatment of thyroid carcinoma. [ABSTRACT FROM AUTHOR]

The role of EGF and TGF-β1 in thyroid cancer is still not clearly defined. TGF-β1 inhibited the cellular growth and migration of follicular (FTC-133) and papillary (B-CPAP) thyroid carcinoma cell lines. Co-treatments of TGF-β1 and EGF inhibited proliferation in both cell lines, but displayed opposite effect on their migratory capability, leading to inhibition in B-CPAP and promotion in FTC-133 cells, by a MAPK-dependent mechanism. TGF-β1, TβRII and EGFR expressions were evaluated in benign and malignant thyroid tumors. Both positivity (51.7% and 60.0% and 80.0% in FA and PTC and FTC) and overexpression (60.0%, 77.7% and 75.0% in FA, PTC and FTC) of EGFR mRNA correlates with the aggressive tumor behavior. The moderate overexpression of TGF-β1 and TβRII mRNA in PTC tissues (61.5% and 62.5%, respectively), counteracted their high overexpression in FTC tissues (100% and 100%, respectively), while EGFR overexpression was similar in both carcinomas. Papillary carcinomas were positive to E-cadherin expression, while the follicular carcinomas lose E-cadherin staining. Our findings of TGF-β1/TβRII and EGFR overexpressions together with a loss of E-cadherin observed in human follicular thyroid carcinomas, and of increased migration ability MAPK-dependent after EGF/TGF-β1 treatments in the follicular thyroid carcinoma cell line, reinforced the hypothesis of a cross-talk between EGF and TGF-β1 systems in follicular thyroid carcinomas phenotype. [ABSTRACT FROM AUTHOR]

In this study we report the green synthesis of nontoxic and stable Cu nanoparticles (NP) using chitosan/starch hydrogel with reducing/capping ability without using any harsh reducing agents. Starch was used as a reducing agent for the synthesis of Cu NPs that was further stabilized by chitosan polymers. The in situ prepared Cu NPs/CS-Starch bio-composite were characterized by advanced physicochemical techniques like Fourier Transformed Infrared spectroscopy (FT-IR), Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), Energy Dispersive X-ray spectroscopy (EDX), X-ray Diffraction (XRD), UV–Vis, TGA and Inductively Coupled Plasma-Optical Emission Spectroscopic (ICP-OES) study. It has been established that Cu NPs/CS-Starch bio-composite have a spherical shape with a mean diameter from 5 to 7 nm. Cell viability of Cu NPs/CS-Starch bio-composite was very low against common human thyroid carcinoma cell lines i.e. TPC1, BCPAP and FTC133 without any cytotoxicity on normal cell line. The best anti-human thyroid carcinoma effects of Cu NPs/CS-Starch bio-composite was observed against the TPC1 cell line. For investigating the antioxidant properties of Cu NPs/CS-Starch bio-composite, the DPPH assay was used in the presence of butylated hydroxytoluene as the positive control. Cu NPs/CS-Starch bio-composite inhibited half of the DPPH molecules in the concentration of 207 µg/mL. The antioxidant activity of Cu NPs/CS-Starch bio-composite is significantly related to its anti-human thyroid carcinoma potentials. Based on to the above findings, the Cu NPs/CS-Starch bio-composite could be administrated for the treatment of several types of human thyroid carcinoma in humans. [ABSTRACT FROM AUTHOR]